Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program
LONDON--(BUSINESS WIRE)--Nov 2, 2023--Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application ...

